Article History
Accepted: 11 May 2021
First Online: 21 June 2021
Competing interests
: D.A.A.V. is a co-founder and shareholder of Novasenta and Tizona, a shareholder of Oncorus and Werewolf, has patents licensed and receives royalties from Astellas and Bristol Myers Squibb, is a scientific advisory board member for Tizona, Werewolf, F-Star and Bicara, is a consultant for Astellas, Bristol Myers Squibb, Almirall and Incyte, and receives research funding from Bristol Myers Squibb, Astellas and Novasenta. The other authors declare no competing interests.